ArticleThe Lancet. Global health2017
Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study.
Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Models for malaria control optimization-a systematic review.Malaria journal · 2024Pooled it
- Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2024Pooled it
- Mass drug administration for malaria.The Cochrane database of systematic reviews · 2021Pooled it
- Agent-based models of malaria transmission: a systematic review.Malaria journal · 2018Pooled it
- Evaluating malaria elimination strategies among military forces in Cambodia: a multi-arm clinical trial comparing monthly prophylaxis and focused screening and treatment.BMC infectious diseases · 2025Trial
- Effect of mass drug administration on malaria incidence in southeast Senegal during 2020-22: a two-arm, open-label, cluster-randomised controlled trial.The Lancet. Infectious diseases · 2025Trial
- Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Moving from Malaria Burden Reduction toward Elimination: An Evaluation of Mass Drug Administration in Southern Province, Zambia.The American journal of tropical medicine and hygiene · 2020Trial
- Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia.The American journal of tropical medicine and hygiene · 2020Trial
- Impact of Four Rounds of Mass Drug Administration with Dihydroartemisinin-Piperaquine Implemented in Southern Province, Zambia.The American journal of tropical medicine and hygiene · 2020Trial
- Trial
- Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.BMC medicine · 2018Trial
- A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial.The Lancet. Global health · 2018Trial
- Mathematical modeling for analyzing mass drug administration operational factors for efficient malaria incidence reduction in southern Senegal.Infectious Disease Modelling · 2026Article
- Implementation, coverage and impact of a programmatic mass drug administration campaign for malaria in southern Mozambique.BMC public health · 2026Article
- A Software Platform for Collaborative Infectious Disease Modeling.Nature health · 2026Article
- Mapping the local effectiveness of mass drug administration for malaria using transportability methods.Nature health · 2026Article
- A stabilized tandem antigen chimera that elicits potent malaria transmission-reducing activity.Nature communications · 2026Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byModel citizen.2017
- Commented on by
Authors and funding
17 authors at 11 institutions in 5 countries.
Funding
Abstract
backgroundMass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission.
methodsWe collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration.
findingsThe models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest.
interpretationMass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.